ArticleDiscover oncology2025
Luteolin regulates pyroptosis of triple-negative breast cancer cells through AKT signaling.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC), the most aggressive molecular subtype of breast cancer, currently lacks effective therapeutic targets. While radiotherapy and chemotherapy remain the mainstay of treatment, therapy resistance frequently develops due to apoptosis evasion, leading to treatment failure. In this study, we demonstrate that luteolin, a naturally occurring flavonoid, effectively induces pyroptosis in TNBC cells through suppression of the AKT signaling pathway. Network pharmacology analysis and Western blot validation confirmed AKT pathway inhibition, with AKT agonists significantly reversing luteolin-induced pyroptosis. Mechanistically, luteolin upregulates the expression of GSDMD and NLRP3 while promoting the release of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), indicating activation of the NLRP3 inflammasome-GSDMD pathway. Our findings highlight luteolin as a promising pyroptosis-inducing agent for TNBC therapy, providing novel insights into targeting the AKT-NLRP3-GSDMD axis to overcome treatment resistance and enhance antitumor immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.